

4/9/01

04-09-2001



101658066

Rc

4-9-01

UNITED STATES PATENT AND TRADEMARK OFFICE

RECORDATION FORM COVER SHEET

PATENTS ONLY

To the Honorable Commissioner of Patents and Trademarks:

Please record the attached original document or copy thereof.

Document ID No.: 101572674

- 1. Name and address of conveying party:

Cell Signaling Technology, Inc.
 166B Cummings Center
 Beverly, MA 01915

A Massachusetts corporation.

- 2. Name and address of receiving party:

Fleet National Bank
 100 Federal Street
 Boston, MA 02110

A national banking association.

- 3. Nature of conveyance: Patent Collateral Assignment and Security Agreement, attached hereto as Exhibit 1.

Execution Date: December 14, 2000

- 4. Patents issued and patents pending:

- A. Patent registration numbers -- None.

RECEIVED
 2001 APR -9 AM 11:14
 ASSIGNMENT SERVICES
 DIVISION

B. Patent application numbers


<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Title</u>
09/148,712	9/4/98	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
PCT/US99/19597	8/26/99	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
09/535,364	3/24/00	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
60/173,939	12/30/99	M. Melnick, et. al.	Regulation of HIV-Tat and Nef By the PAK4 Serine/Threonine Kinase and Its Binding Partners

5. Name and address of party to whom correspondence concerning document should be mailed:

Stephen M. Miklus, Esq.
Bingham Dana LLP
150 Federal Street
Boston, Massachusetts 02110

6. Total number of applications and registrations involved: 4
7. Total fee enclosed: \$0 (\$160.00 previously paid – see attached correspondence)
8. Deposit account number: **[Not applicable]**
9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.



Stephen M. Miklus
April 6, 2001

Total number of pages submitted (including cover sheet and any attached Schedules, and conveyance document and any attached Schedules): 18

Mail documents to be recorded with required cover sheet information to:

United States Patent and Trademark Office
Office of Public Records
Crystal Gateway 4
Room 335
Washington, D.C. 20231

01-05-2001



101572674

UNITED STATES PATENT AND TRADEMARK OFFICE
RECORDATION FORM COVER SHEET
PATENTS ONLY

To the Honorable Commissioner of Patents and Trademarks:

Please record the attached original document or copy thereof.

1. Name and address of conveying party:

Cell Signaling Technology, Inc.
166B Cummings Center
Beverly, MA 01915

A Massachusetts corporation.

2. Name and address of receiving party:

Fleet National Bank
100 Federal Street
Boston, MA 02110

A national banking association.

3. Nature of conveyance: Patent Collateral Assignment and Security Agreement, attached hereto as Exhibit 1.

Execution Date: December 14, 2000

09148712

4. Patents issued and patents pending:

A. Patent registration numbers -- None.

01/04/2001 DNGUYEN 00000116 09148712

01 FC:581

160.00 0P

BUSDOCS: 933720.1

PATENT
REEL: 011647 FRAME: 0293

B. Patent application numbers

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Title</u>
09/148,712	9/4/98	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
PCT/US99/19597	8/26/99	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
09/535,364	3/24/00	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
60/173,939	12/30/99	M. Melnick, et. al.	Regulation of HIV-Tat and Nef By the PAK4 Serine/Threonine Kinase and Its Binding Partners

5. Name and address of party to whom correspondence concerning document should be mailed:

Stephen M. Miklus, Esq.
Bingham Dana LLP
150 Federal Street
Boston, Massachusetts 02110

6. Total number of applications and registrations involved: 4

7. Total fee enclosed: \$160.00

8. Deposit account number: **[Not applicable]**

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.



Stephen M. Miklus
December 14, 2000

Total number of pages submitted (including cover sheet and any attached Schedules, and conveyance document and any attached Schedules): 18

Mail documents to be recorded with required cover sheet information to:

United States Patent and Trademark Office
Office of Public Records
Crystal Gateway 4
Room 335
Washington, D.C. 20231

PATENT COLLATERAL ASSIGNMENT AND SECURITY AGREEMENT

PATENT COLLATERAL SECURITY AND PLEDGE AGREEMENT dated as of December 1, 2000, between CELL SIGNALING TECHNOLOGY, INC., a Massachusetts corporation having its principal place of business at 166B Cummings Center, Beverly, MA 01915, (the "Assignor"), and FLEET NATIONAL BANK, a national banking association having an office at 100 Federal Street, Boston, MA 02110 (the "Bank").

WHEREAS, the Assignor has entered into a Reimbursement Agreement dated as of December 1, 2000 (as amended and in effect from time to time, the "Reimbursement Agreement"), with the Bank, pursuant to which the Bank, subject to the terms and conditions contained therein, is to issue a letter of credit for or otherwise extend credit to the Assignor; and

WHEREAS, the Assignor and the Bank have entered into a Revolving Credit Agreement dated as of December 14, 2000 (as amended and in effect from time to time (the "Loan Agreement"), pursuant to which the Bank, subject to the terms and conditions set forth therein, shall make loans to the Assignor;

WHEREAS, it is a condition precedent to the Bank's issuing any letters of credit, making any loans or otherwise extending credit to the Assignor under the Reimbursement Agreement or the Loan Agreement that the Assignor execute and deliver to the Bank a patent security agreement in substantially the form hereof; and

WHEREAS, the Assignor has executed and delivered to the Bank the Security Agreement dated as of the date hereof (the "Security Agreement"), pursuant to which the Assignor has granted to the Bank a security interest in certain of the Assignor's personal property and fixture assets, including without limitation the patents and patent applications listed on Schedule A attached hereto, all to secure the payment and performance of the Obligations (as defined below); and

WHEREAS, this Patent Agreement is supplemental to the provisions contained in the Security Agreement;

NOW, THEREFORE, in consideration of the premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. DEFINITIONS.

Capitalized terms used herein and not otherwise defined herein shall have the respective meanings provided therefor in the Security Agreement. In addition, the following terms shall have the meanings set forth in this §1 or elsewhere in this Patent Agreement referred to below:

Event of Default. An "Event of Default" under and as defined in the Reimbursement Agreement or the Loan Agreement.

Obligations. All of the indebtedness, obligations and liabilities of the Assignor to the Bank, individually or collectively, whether direct or indirect, joint or several, absolute or contingent, due or to become due, now existing or hereafter arising under or in respect of the Reimbursement Agreement, the Loan Agreement, any promissory notes or other instruments or agreements executed and delivered pursuant thereto or in connection therewith or this Agreement.

Patent Agreement. This Patent Collateral Assignment and Security Agreement, as amended and in effect from time to time.

Patent Collateral. All of the Assignor's right, title and interest in and to all of the Patents, the Patent License Rights, and all other Patent Rights, and all additions, improvements, and accessions to, all substitutions for and replacements of, and all products and Proceeds (including insurance proceeds) of any and all of the foregoing, and all books and records and technical information and data describing or used in connection with any and all such rights, interests, assets or property.

Patent License Rights. Any and all past, present or future rights and interests of the Assignor pursuant to any and all past, present and future licensing agreements in favor of the Assignor, or to which the Assignor is a party, pertaining to any Patents, or Patent Rights, owned or used by third parties in the past, present or future, including the right in the name of the Assignor or the Bank to enforce, and sue and recover for, any past, present or future breach or violation of any such agreement.

Patent Rights. Any and all past, present or future rights in, to and associated with the Patents throughout the world, whether arising under federal law, state law, common law, foreign law, or otherwise, including but not limited to the following: all such rights arising out of or associated with the Patents; the right (but not the obligation) to register claims under any federal, state or foreign patent law or regulation; the right (but not the obligation) to sue or bring opposition or bring cancellation proceedings in the name of the Assignor or the Bank for any and all past, present and future

infringements of or any other damages or injury to the Patents or the Patent Rights, and the rights to damages or profits due or accrued arising out of or in connection with any such past, present or future infringement, damage or injury; and the Patent License Rights.

Patents. All patents and patent applications, whether United States or foreign, that are owned by the Assignor or in which the Assignor has any right, title or interest, now or in the future, including but not limited to:

(a) the patents and patent applications listed on Schedule A hereto (as the same may be amended pursuant hereto from time to time);

(b) all letters patent of the United States or any other country, and all applications for letters patent of the United States or any other country;

(c) all re-issues, continuations, divisions, continuations-in-part, renewals or extensions thereof;

(d) the inventions disclosed or claimed therein, including the right to make, use, practice and/or sell (or license or otherwise transfer or dispose of) the inventions disclosed or claimed therein; and

(e) the right (but not the obligation) to make and prosecute applications for such Patents.

Proceeds. Any consideration received from the sale, exchange, license, lease or other disposition or transfer of any right, interest, asset or property which constitutes all or any part of the Patent Collateral, any value received as a consequence of the ownership, possession, use or practice of any Patent Collateral, and any payment received from any insurer or other person or entity as a result of the destruction or the loss, theft or other involuntary conversion of whatever nature of any right, interest, asset or property which constitutes all or any part of the Patent Collateral.

PTO. The United States Patent and Trademark Office.

2. GRANT OF SECURITY INTEREST.

To secure the payment and performance in full of all of the Obligations, the Assignor hereby grants, assigns, transfers and conveys to the Bank, BY WAY OF COLLATERAL SECURITY, all of the Patent Collateral. THE BANK ASSUMES NO LIABILITY ARISING IN ANY WAY BY REASON OF ITS HOLDING SUCH COLLATERAL SECURITY.

limitation the payment when due of all maintenance fees and other fees, taxes and other expenses which shall be incurred or which shall accrue with respect to any of the Patents. Any expenses incurred in connection with such applications and actions shall be borne by the Assignor. The Assignor shall not abandon any patent application filed with the United States Patent Office, or any pending patent application with the United States Patent Office or patent with the United States Patent Office, without the consent of the Bank, which consent shall not be unreasonably withheld or delayed. The Bank hereby appoints the Assignor as its agent for all matters referred to in the foregoing provisions of this §6 and for all similar matters in foreign countries and agrees to execute any documents necessary to confirm such appointment. Upon the occurrence and during the continuance of an Event of Default, the Bank may terminate such agency by providing written notice of termination to the Assignor.

6.3. Assignor's Enforcement Rights. The Assignor shall have the right, with the consent of the Bank, which shall not be unreasonably withheld, to bring suit or other action in the Assignor's own name to enforce the Patents and the Patent Rights. The Bank shall be required to join in such suit or action as may be necessary to assure the Assignor's ability to bring and maintain any such suit or action in any proper forum so long as the Bank is completely satisfied that such joinder will not subject the Bank to any risk of liability. The Assignor shall promptly, upon demand, reimburse and indemnify the Bank for all damages, costs and expenses, including legal fees, incurred by the Bank pursuant to this §6.

6.4. Protection of Patents, etc. In general, the Assignor shall take any and all such actions (including but not limited to institution and maintenance of suits, proceedings or actions) as may be commercially feasible and as may be necessary or appropriate to properly maintain, protect, preserve, care for and enforce the Patent Collateral. The Assignor shall not take or fail to take any action, nor permit any action to be taken or not taken by others under its control, which would affect the validity, grant or enforcement of any of the Patent Collateral, unless taking such action, failing to take such action, permitting such action to be taken or not taken by others under its control is not commercially feasible.

6.5. Notification by Assignor. Promptly upon obtaining knowledge thereof, the Assignor will notify the Bank in writing of the institution of, or any final adverse determination in, any proceeding in the PTO or any similar office or agency of the United States or any foreign country, or any court, regarding the validity of any of the Patents or the Assignor's rights, title or interests in and to any of the Patent Collateral, and of any event which does or reasonably could materially adversely affect the value of any of the Patent

Collateral, the ability of the Assignor or the Bank to dispose of any of the Patent Collateral or the rights and remedies of the Bank in relation thereto (including but not limited to the levy of any legal process against any of the Patent Collateral).

7. LICENSE BACK TO ASSIGNOR.

Unless and until there shall have occurred and be continuing an Event of Default and the Bank has notified the Assignor that the license granted hereunder is terminated, the Bank hereby grants to the Assignor the sole and exclusive, nontransferable, royalty-free, worldwide right and license under the Patents to make, have made for it, use, sell and otherwise practice the inventions disclosed and claimed in the Patents for the Assignor's own benefit and account and for none other; provided, however, that the foregoing right and license shall be no greater in scope than, and limited by, the rights assigned to the Bank by the Assignor hereby. The Assignor agrees not to sell, assign, transfer, encumber or sublicense its interest in the license granted to the Assignor in this §7, without the prior written consent of the Bank, which consent shall not be unreasonably withheld or delayed. Any such sublicenses granted on or after the date hereof shall be terminable by the Bank upon termination of the Assignor's license hereunder.

8. REMEDIES.

If any Event of Default shall have occurred and be continuing, then upon notice by the Bank to the Assignor: (i) the Assignor's license with respect to the Patents as set forth in §7 shall terminate; (ii) the Assignor shall immediately cease and desist from the practice, manufacture, use and sale of the inventions claimed, disclosed or covered by the Patents; and (iii) the Bank shall have, in addition to all other rights and remedies given it by this Patent Agreement, the Reimbursement Agreement, the Loan Agreement, the Security Agreement, and the other documents created and delivered in connection therewith, those allowed by law and the rights and remedies of a secured party under the Uniform Commercial Code as enacted in the Commonwealth of Massachusetts and, without limiting the generality of the foregoing, the Bank may immediately, without demand of performance and without other notice (except as set forth next below) or demand whatsoever to the Assignor, all of which are hereby expressly waived, and without advertisement, sell or license at public or private sale or otherwise realize upon the whole or from time to time any part of the Patent Collateral, or any interest which the Assignor may have therein, and after deducting from the proceeds of sale or other disposition of the Patent Collateral all expenses (including all reasonable expenses for broker's fees and legal services), shall apply the residue of such proceeds toward the payment of the Obligations as

set forth in the Security Agreement. Notice of any sale, license or other disposition of any of the Patent Collateral shall be given to the Assignor at least five (5) days before the time that any intended public sale or other disposition of such Patent Collateral is to be made or after which any private sale or other disposition of such Patent Collateral may be made, which the Assignor hereby agrees shall be reasonable notice of such public or private sale or other disposition. At any such sale or other disposition, the Bank may, to the extent permitted under applicable law, purchase or license the whole or any part of the Patent Collateral or interests therein sold, licensed or otherwise disposed of.

9. COLLATERAL PROTECTION.

If the Assignor shall fail to do any act that it has covenanted to do hereunder, or if any representation or warranty of the Assignor shall be breached, the Bank, in its own name or that of the Assignor (in the sole discretion of the Bank), may (but shall not be obligated to) do such act or remedy such breach (or cause such act to be done or such breach to be remedied), and the Assignor agrees promptly to reimburse the Bank for any cost or expense incurred by the Bank in so doing.

10. POWER OF ATTORNEY.

If any Event of Default shall have occurred and be continuing, the Assignor does hereby make, constitute and appoint the Bank (and any officer or agent of the Bank as the Bank may select in its exclusive discretion) as the Assignor's true and lawful attorney-in-fact, with the power to endorse the Assignor's name on all applications, documents, papers and instruments necessary for the Bank to use any of the Patent Collateral, to practice, make, use or sell the inventions disclosed or claimed in any of the Patent Collateral, to grant or issue any exclusive or nonexclusive license of any of the Patent Collateral to any third person, or necessary for the Bank to assign, pledge, convey or otherwise transfer title in or dispose of the Patent Collateral or any part thereof or interest therein to any third person, and, in general, to execute and deliver any instruments or documents and do all other acts which the Assignor is obligated to execute and do hereunder. The Assignor hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof, and releases the Bank from any claims, liabilities, causes of action or demands arising out of or in connection with any action taken or omitted to be taken by the Bank under this power of attorney (except for the Bank's gross negligence or willful misconduct). This power of attorney shall be irrevocable for the duration of this Patent Agreement.

11. FURTHER ASSURANCES.

The Assignor shall, at any time and from time to time, and at its expense, make, execute, acknowledge and deliver, and file and record as necessary or appropriate with governmental or regulatory authorities, agencies or offices, such agreements, assignments, documents and instruments, and do such other and further acts and things (including, without limitation, obtaining consents of third parties), as the Bank may request or as may be necessary or appropriate in order to implement and effect fully the intentions, purposes and provisions of this Patent Agreement, or to assure and confirm to the Bank the grant, perfection and priority of the Bank's security interest in any of the Patent Collateral.

12. TERMINATION.

At such time as all of the Obligations have been finally paid and satisfied in full, this Patent Agreement shall terminate and the Bank shall, upon the written request and at the expense of the Assignor, execute and deliver to the Assignor all deeds, assignments and other instruments as may be necessary or proper to reassign and reconvey to and re-vest in the Assignor the entire right, title and interest to the Patent Collateral previously granted, assigned, transferred and conveyed to the Bank by the Assignor pursuant to this Patent Agreement, as fully as if this Patent Agreement had not been made, subject to any disposition of all or any part thereof which may have been made by the Bank pursuant hereto or the Security Agreement.

13. COURSE OF DEALING.

No course of dealing among the Assignor and the Bank, nor any failure to exercise, nor any delay in exercising, on the part of the Bank, any right, power or privilege hereunder or under the Security Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

14. EXPENSES.

Any and all fees, costs and expenses, of whatever kind or nature, including the reasonable attorneys' fees and legal expenses incurred by the Bank in connection with the preparation of this Patent Agreement and all other documents relating hereto, the consummation of the transactions contemplated hereby or the enforcement hereof, the filing or recording of any documents (including all taxes in connection therewith) in public offices, the payment or discharge of any taxes, counsel fees, maintenance fees,

18. NOTICES.

All notices and other communications made or required to be given pursuant to this Patent Agreement shall be in writing and shall be delivered in hand, mailed by United States registered or certified first-class mail, postage prepaid, or sent by telegraph, telecopy or telex and confirmed by delivery via courier or postal service, addressed as follows:

(a) if to the Assignor, at Cell Signaling Technology, Inc., 166B Cummings Center, Beverly, MA 01915, Attention: _____, or at such other address for notice as the Assignor shall last have furnished in writing to the person giving the notice; and

(b) if to the Bank, at Fleet National Bank, 100 Federal Street, Boston, MA 02110, Attention: _____, or at such other address for notice as the Bank shall last have furnished in wiring to the person giving the notice.

Any such notice or demand shall be deemed to have been duly given or made and to have become effective (i) if delivered by hand to a responsible officer of the party to which it is directed, at the time of the receipt thereof by such officer, (ii) if sent by registered or certified first-class mail, postage prepaid, two (2) Business Days after the posting thereof, and (iii) if sent by telegraph, telecopy, or telex, at the time of the dispatch thereof, if in normal business hours in the country of receipt, or otherwise at the opening of business on the following Business Day.

19. AMENDMENT AND WAIVER.

This Patent Agreement is subject to modification only by a writing signed by the Bank and the Assignor, except as provided in §5.2. The Bank shall not be deemed to have waived any right hereunder unless such waiver shall be in writing and signed by the Bank. A waiver on any one occasion shall not be construed as a bar to or waiver of any right on any future occasion.

20. GOVERNING LAW; CONSENT TO JURISDICTION.

THIS PATENT AGREEMENT IS INTENDED TO TAKE EFFECT AS A SEALED INSTRUMENT AND SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE COMMONWEALTH OF MASSACHUSETTS. The Assignor agrees that any suit for the enforcement of this Patent Agreement may be brought in the courts of the Commonwealth of Massachusetts or any federal court sitting therein and consents to the non-exclusive jurisdiction of such court and to

service of process in any such suit being made upon the Assignor by mail at the address specified in §18. The Assignor hereby waives any objection that it may now or hereafter have to the venue of any such suit or any such court or that such suit is brought in an inconvenient court.

21. WAIVER OF JURY TRIAL.


THE ASSIGNOR WAIVES ITS RIGHT TO A JURY TRIAL WITH RESPECT TO ANY ACTION OR CLAIM ARISING OUT OF ANY DISPUTE IN CONNECTION WITH THIS PATENT AGREEMENT, ANY RIGHTS OR OBLIGATIONS HEREUNDER OR THE PERFORMANCE OF ANY SUCH RIGHTS OR OBLIGATIONS. Except as prohibited by law, the Assignor waives any right which it may have to claim or recover in any litigation referred to in the preceding sentence any special, exemplary, punitive or consequential damages or any damages other than, or in addition to, actual damages. The Assignor (i) certifies that neither the Bank nor any representative, agent or attorney of the Bank has represented, expressly or otherwise, that the Bank would not, in the event of litigation, seek to enforce the foregoing waivers, and (ii) acknowledges that, in entering into the Reimbursement Agreement and the Loan Agreement, the Bank is relying upon, among other things, the waivers and certifications contained in this §21.

22. MISCELLANEOUS.


The headings of each section of this Patent Agreement are for convenience only and shall not define or limit the provisions thereof. This Patent Agreement and all rights and obligations hereunder shall be binding upon the Assignor and its successors and assigns, and shall inure to the benefit of the Bank and its successors and assigns. In the event of any irreconcilable conflict between the provisions of this Patent Agreement and the Reimbursement Agreement or the Loan Agreement, or between this Patent Agreement and the Security Agreement, the provisions of the Reimbursement Agreement or the Loan Agreement or the Security Agreement, as the case may be, shall control. If any term of this Patent Agreement shall be held to be invalid, illegal or unenforceable, the validity of all other terms hereof shall in no way be affected thereby, and this Patent Agreement shall be construed and be enforceable as if such invalid, illegal or unenforceable term had not been included herein. The Assignor acknowledges receipt of a copy of this Patent Agreement.

IN WITNESS WHEREOF, this Patent Agreement has been executed as of the day and year first above written.

CELL SIGNALING TECHNOLOGY,
INC.

By: 
Name: **RICHARD H. IRELAND**
Title: **TREASURER**

FLEET NATIONAL BANK

By: 
Name: Pamela A. Kuong
Title: Vice President

CERTIFICATE OF ACKNOWLEDGMENT

COMMONWEALTH OR STATE OF MASSACHUSETTS
) ss.
COUNTY OF SUFFOLK)

Before me, the undersigned, a Notary Public in and for the county aforesaid, on this 15th day of December, 2000 personally appeared Richard A. Tamsvan to me known personally, and who, being by me duly sworn, deposes and says that he is the Tamsvan of Cell Signaling Technology, Inc., and that said instrument was signed and sealed on behalf of said corporation by authority of its Board of Directors, and said Tamsvan acknowledged said instrument to be the free act and deed of said corporation.

[Signature]
Notary Public Jan S. Albert
My commission expires: 6/21/2002

SCHEDULE A

ISSUED AND PENDING PATENTS

**Patents Issued by U.S. Patent
and Trademark Office**

<u>Patent No.</u>	<u>Issue Date</u>	<u>Inventor(s)</u>	<u>Title</u>
-------------------	-------------------	--------------------	--------------

**Patents Pending with U.S. Patent
and Trademark Office**

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Title</u>
09/148,712	9/4/98	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
PCT/US99/19597	8/26/99	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
09/535,364	3/24/00	M. Comb, et. al.	Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
60/173,939	12/30/99	M. Melnick, et. al.	Regulation of HIV-Tat and Nef By the PAK4 Serine/Threonine Kinase and Its Binding Partners